Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
Top Cited Papers
- 9 January 2025
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 21 (5) , 289-300
Abstract
Immune-related adverse events (irAEs), including endocrine irAEs, can occur in response to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Of the endocrine irAEs, pituitary and thyroid irAEs are most frequently observed, followed by primary adrenal insufficiency, type 1 diabetes mellitus and hypoparathyroidism. Notably, pituitary irAEs and type 1 diabetes mellitus can be lethal if overlooked, potentially leading to adrenal crisis and diabetic ketoacidosis, respectively. On the other hand, pituitary and thyroid irAEs are reported to be associated with more favourable prognoses in some cancers if treated appropriately with hormone-replacement therapies. It would be useful to identify those people who are likely to develop endocrine irAEs before initiating therapy with ICIs. Anti-pituitary antibodies and thyroid autoantibodies have been identified as potential biomarkers for the development of pituitary and thyroid irAEs, respectively. This Review elaborates on the clinical characteristics and management strategies of several endocrine irAEs, using the latest research findings and guidelines published by several academic societies.Keywords
This publication has 118 references indexed in Scilit:
- Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare DiseaseThe Oncologist, 2012
- Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical EndocrinologistsEndocrine Practice, 2011
- Clinical Applications of Diabetes Antibody TestingThe Journal of Clinical Endocrinology & Metabolism, 2010
- Ipilimumab-Induced Hypophysitis: MR Imaging FindingsAmerican Journal of Neuroradiology, 2009
- HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes RiskDiabetes, 2008
- Autoimmune Polyendocrine Syndrome Type 1 and NALP5, a Parathyroid AutoantigenNew England Journal of Medicine, 2008
- The Calcium-Sensing Receptor Is a Target of Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1The Journal of Clinical Endocrinology & Metabolism, 2007
- Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic MelanomaJournal of Immunotherapy, 2006
- Autoimmune HypophysitisEndocrine Reviews, 2005
- Italian Addison Network Study: Update of Diagnostic Criteria for the Etiological Classification of Primary Adrenal InsufficiencyThe Journal of Clinical Endocrinology & Metabolism, 2004